Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Genetic Research » Veracyte's Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy

Veracyte's Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy

Mar 02, 2020
|
staff reporter

NEW YORK – A new retrospective study published in NPJ Breast Cancer on Monday suggests that Veracyte's Prosigna breast cancer prognostic gene signature assay can identify the subgroups of patients who are more likely to benefit from aggressive chemotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
23
Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Apr
21
Featured Webinar

Single-cell Multiomics Analysis of Clonal Evolution in Myeloid Malignancies

Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

What's Popular?

In Genetic Research

  1. Human Pangenome Reference Consortium Releases Data From 30 Genomes

  2. Fauna Bio Gets $373K NIH Grant to Study Animal Genomes for Potential Drug Targets

  3. Induced Pluripotent Stem Cells Show Potential for Finding New Regulatory Variants

  4. Finnish Population Genetic Analysis Reflects Recent Historical Events

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.